Daily amylin replacement reverses hepatic glycogen depletion in insulin‐treated streptozotocin diabetic rats

Young, Andrew; Crocker, Leslie B.; Wolfe-Lopez, Deborah; Cooper, Garth J. S.

doi:10.1016/0014-5793(91)80051-4

Cited by 24 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Native amylin has been reported to normalize hepatic glycogen stores in insulin-treated streptozocin diabetic rats [4], an effect presumed to be secondary to increased hepatic lactate supply from muscle [27]. However a suppresion of glucagon levels by normalized amylin levels leading to increased liver glycogen content remains a possibility.…”

Section: Discussionmentioning

confidence: 99%

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

Ørskov¹,

Nyholm

Hove

et al. 1999

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

Ørskov¹,

Nyholm

Hove

et al. 1999

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

“…Tissue-specific CGRP levels would be a more accurate measure of physiological effect of CGRP, as plasma CGRP levels might be due to spillover (22). Pre-clinical studies showed that increased pancreatic storage of CGRP results in insulin resistance (43,74). However, studies using radioimmunoassay, radio-receptor assay, and immunoradiometric assay demonstrated a strong correlation between the levels of CGRP in plasma and tissue extracts of rats and humans (22,24).…”

Section: Discussionmentioning

confidence: 99%

“…The role of CGRP in glucose homeostasis is diverse and complex, given its presence in the central, peripheral, and enteric nervous system, as well as the pancreas (23,27). Studies conducted predominantly in obese and type 2 diabetic rats have shown that infusion of pharmacological doses of CGRP induces insulin resistance and decreases peripheral glucose clearance (15,24,(42)(43)(44)(45)(46)(47). Whether this holds true in patients with CHAP is not known.…”

Section: Discussionmentioning

confidence: 99%

Calcitonin gene-related peptide: neuroendocrine communication between the pancreas, gut, and brain in regulation of blood glucose

et al. 2017

View full text Add to dashboard Cite

Background: Calcitonin gene-related peptide (CGRP), a ubiquitous neuropeptide, plays a diverse and intricate role in chronic low-grade inflammation, including conditions such as obesity, type 2 diabetes, and diabetes of the exocrine pancreas. Diabetes of exocrine pancreas is characterised by chronic hyperglycemia and is associated with persistent low-grade inflammation and altered secretion of certain pancreatic and gut hormones. While CGRP may regulate glucose homeostasis and the secretion of pancreatic and gut hormones, its role in chronic hyperglycemia after acute pancreatitis (CHAP) is not known. The aim of this study was to investigate the association between CGRP and CHAP.Methods: Fasting blood samples were collected to measure insulin, HbA1c, CGRP, amylin, C-peptide, glucagon, pancreatic polypeptide (PP), somatostatin, gastric inhibitory peptide, glicentin, glucagon-like peptide-1 and 2, and oxyntomodulin. Modified Poisson regression analysis and linear regression analyses were conducted. Five statistical models were used to adjust for demographic, metabolic, and pancreatitisrelated risk factors.Results: A total of 83 patients were recruited. CGRP was significantly associated with CHAP in all five models (P-trend <0.005). Further, it was significantly associated with oxyntomodulin (P<0.005) and glucagon (P<0.030). Oxyntomodulin and glucagon independently contributed 9.7% and 7%, respectively, to circulating CGRP variance. Other pancreatic and gut hormones were not significantly associated with CGRP.Conclusions: CGRP is involved in regulation of blood glucose in individuals after acute pancreatitis. This may have translational implications in prevention and treatment of diabetes of the exocrine pancreas.

show abstract

“…It has previously been postulated that amylin deficiency could aggravate hypoglycaemia in insulin-treated patientsp,35] The concurrent administration of amylin with insulin elicited a dosedependent response in amylin-deficient diabetic rats with restoration of normal hepatic glycogen levels, a finding that was interpreted as consistent with amylin-mediated stimulation of the indirect Cori cycle. [132] Amylin also enhances the stimulation of hepatic glucose production by glucagon and the recovery from insulin-induced hypoglycaemia in normal rats) 68] A recent study of acute administration of an amylin analogue has generated preliminary evidence for a beneficial effect of parenterally administered amylin in insulin-treated human patients with IDDM. [133] In amylin-treated patients, postprandial hyperglycaemic excursions were decreased compared with matched controls.…”

Section: Amylin-insulin Mixtures In Insulin-dependent Diabetes Mellitusmentioning

confidence: 97%

Amylin, Amyloid and Age-Related Disease

Cooper

Tse

1996

Drugs & Aging

Self Cite

View full text Add to dashboard Cite

Amylin, a 37-amino acid peptide, is cosecreted with insulin from the beta-cells of the pancreatic islets in normal response to physiological stimuli. It is the major protein of islet amyloid, which is usually present in the pancreases of people with non-insulin-dependent (type II) diabetes mellitus. Amylin elicits potent effects on carbohydrate metabolism in rodent tissues, causing insulin resistance in skeletal muscle and liver. A close structural relationship exists between amylin and the 2 calcitonin gene-related peptides, which are widely distributed neuropeptides and potent vasodilators. These exert biological effects similar to those of amylin on the organs primarily responsible for the regulation of carbohydrate metabolism. All 3 peptides are thought to cause their biological actions by binding to similar cell surface receptors. This article reviews the field of amylin and its role in the physiological regulation of carbohydrate metabolism, and in disease mechanisms associated with insulin resistance in diabetes mellitus, impaired glucose tolerance and essential hypertension. Potential therapeutic applications are also discussed.

show abstract

Daily amylin replacement reverses hepatic glycogen depletion in insulin‐treated streptozotocin diabetic rats

Cited by 24 publications

References 25 publications

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

Calcitonin gene-related peptide: neuroendocrine communication between the pancreas, gut, and brain in regulation of blood glucose

Amylin, Amyloid and Age-Related Disease

Contact Info

Product

Resources

About